perhaps in a more subtle form. We have deliberately used 'corrective formulas' as advocated in the literature to 'adjust' creatinines for use in the MDRD formula in our article. It appears that this so-called 'improvement' only leads to even more biased results if inapt formulae are used for correction. This is at the end of the conclusions of our article. It is maybe good that this point is stressed again, and even better emphasized in this letter. Dr Delanaye and colleagues also point to some recent developments in this field, as proposed by Levey et al. at the recent ASN meeting. I fully agree that isotope dilution mass spectrometry-referenced or traceable determinations of creatinine can improve standardization, but that it remains to be proven whether the MDRD population is 'broad enough' to serve as a reference population for patients in CKD stage 1 or 2, and whether Jaffe´-based creatinine determinations are reliable enough in these patients. Whereas, it is clear that enormous progress has been made in this field over the last two years, to a great extent attributable to the actions of the KDIGO initiative, it is also clear that a long road lies ahead before we dispose of a simple, reliable and cheap tool to detect patients at risk for decreased renal function.
Rho/Rho-kinase and C-reactive protein relationship in hypertension and atherosclerosis
Sir, RhoA/Rho kinase pathway has been advanced in the pathogenesis of hypertension and atherosclerosis [1] . This is based on its modulation of regulatory chain phosphorylation of myosin II which contributes to smooth muscle Ca 2þ sensitization [2] , increased expression of NAD(P)H oxidase [3] and induction of oxidative stress. In addition, Rho kinase activation regulates endothelial nitric oxide synthase [4] and also controls the production of the profibrotic plasminogen activator inhibitor-1 (PAI-1) [5] and inhibition of Rho kinase results in the suppression of neointimal formation [6] , activation of Akt pathway and eNOS [7] , further confirming an important role of Rho/Rho kinase inhibition for cardiovascular protection and prevention of atherogenesis. Evidence has been recently provided for the involvement of Rho/Rho-kinase signaling in C Reactive Protein (CRP)-induced atherothrombogenesis. CRP has been shown, in fact, to activate Rho/Rho-kinase signaling, which through activation of NFkB activity results in PAI-1 expression, known atherothrombogenic factor. This suggests Rho/ Rho-kinase inhibition as a potential therapeutic strategy for the prevention of atherogenesis [8] .
The recent results from our ongoing studies in patients with Bartter's and Gitelman's syndrome (BS/GS) [9, 10] provide additional support as well as additional evidence for the importance of Rho/Rho kinase signaling-CRP relationship in atherothrombogenesis. Of direct relevance is our recent demonstration in BS/GS patients that RhoA/Rho kinase pathway is blunted as shown by the reduced gene and protein expression and response to angiotensin II (Ang II) challenge of Rho kinase and PAI-1 [11] , and by the reduced gene and protein expression of the upstream regulator of RhoA, p115RhoGEF [12] . BS/GS, caused by gene defects in specific kidney transporters and ion channels, presents a puzzling clinical picture characterized by hypokalaemia, sodium depletion, activation of the renin-angiotensin-aldosterone system (RAAS), with increased plasma levels of Ang II and aldosterone, yet normo/hypotension, reduced peripheral resistance, and hyporesponsiveness to pressor agents [9, 10] . BS/GS has been considered a good human model to explore the mechanisms responsible for maintenance/controlling vascular tone and vascular remodeling [10, 13] . In fact, understanding why patients with BS/GS do not develop hypertension and its complications such as cardiovascular remodeling and atherogenesis in spite of high Ang II and activation of RAAS, sheds considerable light on the cellular basis of hypertension. In BS/GS specifically, the short-term Ang II signaling pathway is blunted as documented by the increased regulator of G-protein signaling-2 [14] reduced Gq gene and protein expression [15, 16] and reduced related downstream cellular events such as intracellular Ca 2þ and IP 3 release, and PKC activity [15, 17, 18] . The long-term signaling pathway of Ang II, which modulates the cell redox state to promote cardiovascular remodeling and atherosclerosis, is also altered in BS/GS [19, 20] . The reduced peripheral resistance, vascular hyporeactivity, and normohypotension typical of BS/GS patients and their collection of biochemical characteristics present, therefore, a mirror image of those found in hypertension. The downregulation of Rho/Rho kinase pathway noted in our recent studies occurred in the context of the increased level of the endothelial subunit of NO synthase (eNOS) mRNA [21] alongside elevated urinary NO metabolites and cGMP levels [22] , which parallels in humans the upregulation of the NO system upon Rho kinase inhibition recently shown in vitro in endothelial cells [7] and in vivo in Dahl rats [23] . More importantly, we have very recently found in BS/GS patients compared with normotensive healthy subjects, unchanged CRP plasma level as well as acute phase reactants such as serum amyloid A, VCAM and ICAM, and inflammatory process related cytokines such as interleukin 6 and TNF [24] . The BS/GS patients' unchanged level of CPR [24] together with their downregulated Rho/Rho kinase pathway [11, 12] , reduced PAI-1 gene and protein expression [11] and unchanged plasma level of the inflammatory cytokines interleukin 6 and TNF [24] , whose expression is known to be dependent on NFkB activity, also provide in a human model of altered vascular tone regulation, confirmatory data in support of those derived from in vitro studies [8] . In addition, our findings in BS/GS could also shed some light on the molecular mechanisms involved in CRP-induced gene expression. One possible mechanism for the CRP-induced gene expression is, in fact, the activation of NFkB through the RhoA induced phosphorylation of the inhibitory subunit IkB [25] and the activation of IkB kinase by Rho kinase [26] .
Relevant to this mechanism, we have preliminary data that, instead, show in BS/GS patients compared with normotensive healthy subjects, an increased expression of IkB while NFkB is unchanged, which is in keeping with a reduced activity of NFkB (Calo`LA and Pagnin E, personal observation).
In conclusion, the overall clinical, biochemical and molecular picture of BS/GS may contribute to an understanding in humans of the molecular mechanism of CRP/Rho/Rho kinase/NfkB relationship that determines the involvement of CRP in atherothrombogenesis demonstrated in vitro [8] and thus confirming the utility of Rho/Rho kinase inhibition for cardiovascular protection in humans.
